Cardiola is expanding the targeted patient population which may benefit from the CE-marked m.pulse Muscular Counter Pulsation (MCP)-based system.
‘MCP’ stimulates a patient’s muscle groups electrically and affects their contraction in synchronization with the early diastole cardiac cycle, which acts to relieve the heart from workload and improve blood flow.
Cardiola’s m.pulse device, based on MCP technology, is approved in Europe for treating heart failure.
Battery-powered m.pulse, the size of a cell phone that only during treatment is attached to the patient, is synchronized to cardiac cycle to stimulate the muscles of the calves and thighs to make them contract in the resting phase of the heart.
Cardiola CEO and former Global Innovation Manager at Siemens Medical Christof Lenz said it has been well-documented clinically that MCP — the proprietary technology platform of our patented m.pulse device, is a safe and effective therapy designed to improve the hemodynamic function of a failing heart.